Source: Virtual Congress 2021 – Pulmonary embolism in non-COVID-19 and COVID-19 patients



Rating:

Share or cite this content

Citations should be made in the following way:
K. Mclaren (Edinburgh, United Kingdom), J. Tiernan (Edinburgh, United Kingdom), M. Pass (Edinburgh, United Kingdom), A. Lithgow (Edinburgh, United Kingdom), A. Mirchandani (Edinburgh, United Kingdom), V. Tilliridou (Edinburgh, United Kingdom), J. Anderson (Edinburgh, United Kingdom), A. Page (Edinburgh, United Kingdom), J. Murchison (Edinburgh, United Kingdom), R. Dickinson (Edinburgh, United Kingdom). Pulmonary emboli and COVID-19: an increased risk for all?. 494

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary embolism risk stratification: where are we heading? Source: Eur Respir J 2014; 43: 298-300 Year: 2004 Pulmonary embolism and COVID-19: a “special phenotype”? Source: Virtual Congress 2021 – Pulmonary embolism in non-COVID-19 and COVID-19 patients Year: 2021 Pulmonary embolism in young people: risk factors and clinical presentation Source: Annual Congress 2008 - COPD epidemiology Year: 2008 Pulmonary embolism and pulmonary hypertension - is our follow up adequate? Source: Eur Respir J 2005; 26: Suppl. 49, 270s Year: 2005 Electrocardiographic abnormalities in patients with low or moderate risk pulmonary embolism: Prevalence and association with PO2 /FiO2 ratio Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Pulmonary embolism and the consequences for the right heart Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-42-1, page=136 Year: 2006 Pulmonary embolism severity index is superior to the Geneva score at predicting which patients with suspected pulmonary embolism are at increased risk of death Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Fatal pulmonary embolism in young people: risk factors and clinical presentation Source: Annual Congress 2009 - Intensive care unit management and outcome Year: 2009 Pulmonary vascular disease(PC) and risk of mortality in patients with idiopathic pulmonary fibrosis(IPF) Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Covid-19 and pulmonary embolism : A heterogeneous association Source: Virtual Congress 2021 – Pulmonary embolism in non-COVID-19 and COVID-19 patients Year: 2021 Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease Source: Eur Respir J 2011; 39: 125-132 Year: 2012 Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease Source: Eur Respir J 2012; 39: 125-132 Year: 2012 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 The management and follow-up of pulmonary embolism (PE) at a district general hospital: Are we missing CTEPH? Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pulmonary hypertension in the elderly: a different disease? Source: Breathe 2016; 12: 43-49 Year: 2016 Chronic thromboembolic pulmonary hypertension in acute pulmonary embolism: A risk factor evaluation study Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Factors related with complications in patients with pulmonary embolism Source: Annual Congress 2005 - News about pulmonary embolism Year: 2005 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021 Hypoperfusion is the main risk factor for the development of non-tuberculous mycobacterial lung disease in CTEPH Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015